SKYE

Over the past six months, Skye Bioscience's stock experienced an 8 to 1 reverse stock split on August 24, 2026. The stock price declined significantly by 95.58% from $38.00 on October 3, 2025, to $1.68 on October 2, 2026, and trended down by 69.91% in the past six months. Its 52-week range was from a high of $14.08 to a low of $1.50. On August 14, 2026, Skye Bioscience announced an agreement to acquire Redx Pharma, forming Fibrx Therapeutics, which led to a 6% rise in SKYE shares after hours, supported by approximately $125 million in committed financings. Earlier, on March 5, 2026, the stock price plummeted by 60% after the company reported that its nimacimab monotherapy did not achieve weight loss compared to a placebo in a mid-stage trial, though nimacimab in combination with semaglutide showed clinically meaningful weight loss and a favorable safety profile. The company reported Q2 2026 earnings on August 13, 2026, with an EPS of -$2.16, meeting expectations, and Q1 2026 financial results on May 11/12, 2026. On May 20, 2026, Cohort 2 of the CBeyond Expansion Study was approved based on favorable safety data. Insider selling was noted, with Andrew Schwab selling shares for $239,555 on September 25, 2026, and 5AM Partners VII, LLC selling 33,892 shares on September 19, 2026.